2. Search Result
Search Result
Results for "

Methamphetamine

" in MedChemExpress (MCE) Product Catalog:

37

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Inhibitory Antibodies

5

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N2332A
    Methyllycaconitine citrate
    Maximum Cited Publications
    43 Publications Verification

    MLA citrate

    		 nAChR Neurological Disease
    Methyllycaconitine (MLA) citrate is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine citrate alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine citrate prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine citrate can be used for neurological disease research, such as Alzheimer’s disease .
    Methyllycaconitine citrate
  • HY-175188
    MT-110

    BPN-0027490

    		 Myosin Neurological Disease
    MT-110 (BPN-0027490) is a non-muscle myosin NMIIB-selective inhibitor with high brain penetration and favorable safety profile. MT-110 specifically disrupts NMIIB-dependent actin dynamics in dendritic spines, while it exerts no significant adverse effects on cardiac myosin II and cardiac functions (such as cardiac output and heart rate) at tested concentrations. A single administration of MT-110 produces long-lasting (sustained for several weeks) blockade of methamphetamine motivation associated with environmental cues. MT-110 exhibits extremely high specificity, with no interference with cocaine motivation, hippocampus-dependent memory, fear memory, or locomotor and anxiety-like behaviors. MT-110 serves as a valuable tool compound for investigating the mechanisms of methamphetamine use disorder .
    MT-110
  • HY-N0541
    Pseudoginsenoside F11
    2 Publications Verification

    Ginsenoside A1

    		 Endogenous Metabolite Others
    Pseudoginsenoside F11 (Ginsenoside A1), a component of Panax quinquefolium (American ginseng), has been demonstrated to antagonize the learning and memory deficits induced by scopolamine, morphine and methamphetamine in mice.
    Pseudoginsenoside F11
  • HY-Z0283
    Benzamide
    1 Publications Verification

    Benzenecarboxamide; Phenylamide

    		 Endogenous Metabolite PARP Others
    Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide
  • HY-107541
    O-1602
    1 Publications Verification

    		 GPR55 Neurological Disease
    O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
    O-1602
  • HY-147428
    Zolunicant

    MM-110; (±)​-18-Methoxycoronaridine

    		 nAChR Parasite Infection Neurological Disease
    Zolunicant (MM-110) is a potent inhibitor against nicotinic α3β4 receptors with an IC50 of 0.90 μM to combat addiction. Zolunicant can decrease the self-administration of several addictive agents including morphine, methamphetamine, nicotine, and ethanol in rat model. Zolunicant can be studied as a potential research for multiple forms of agent abuse . Zolunicant also reveals a potent leishmanicide effect against Leishmania amazonensis .
    Zolunicant
  • HY-16639
    ML314

    		GPR35 Neurotensin Receptor Neurological Disease Endocrinology
    ML314 is a potent, BBB-penetrant and β-arrestin biased molecule agonist of NTR1 (EC50 = 1.9 μM). ML314 shows good selectivity against NTR2 and GPR35, but does not stimulate Ca2+ mobilization. ML314 can attenuate amphetamine-like hyperlocomotion in dopamine transporter knockout mice. ML314 attenuates methamphetamine-associated hyperlocomotion and potentiates the psychostimulant inhibitory effects of a ghrelin antagonist in wild type mouse model. ML314 also acts as an allosteric enhancer of endogenous neurotensin. ML314 antagonizes G protein signaling. ML314 can be studied in research for methamphetamine abuse conditions .
    ML314
  • HY-147395
    GPR52 agonist-1

    		GPR52 Neurological Disease
    GPR52 agonist-1 is a potent, orally active and blood-brain barrier (BBB) penetrant GPR52 agonist with an pEC50 value of 7.53. GPR52 agonist-1 affects cAMP accumulation through direct interaction with GPR52. GPR52 agonist-1 can significantly suppress Methamphetamine-induced hyperactivity in mice. Antipsychotic activity .
    GPR52 agonist-1
  • HY-132225
    SB 206553

    		5-HT Receptor Inflammation/Immunology
    SB 206553 is a 5-HT2C inverse agonist. SB 206553 can attenuate methamphetamine-seeking in rats. SB 206553 has activity for 5-HT2 receptor ligands in HEK-293 or CHO-K1 cells expressing human recombinant 5-HT2 receptors with pKi values of 5.6 nM (5-HT2A), 7.7 nM (5-HT2B) and 7.8 nM (5-HT2C), respectively. SB 206553 can be used for the research of psychostimulant abuse disorders .
    SB 206553
  • HY-B1694A
    Methoxyphenamine hydrochloride

    NSC-65644

    		 Adrenergic Receptor Inflammation/Immunology Endocrinology
    Methoxyphenamine hydrochloride, a non-regulated analog of Methamphetamine, is a β-adrenergic receptor agonist used as a bronchodilator .
    Methoxyphenamine hydrochloride
  • HY-NP142
    Methamphetamine-BSA

    MA-BSA

    		 Biochemical Assay Reagents Neurological Disease
    Methamphetamine-BSA is a protein consists of Methamphetamine and Bovine Serum Albumin (BSA). Methamphetamine-BSA is an antigen to generate specific antibodies for the detection of Methamphetamine in biological samples .
    Methamphetamine-BSA
  • HY-121609A
    Pholedrine hydrochloride

    		Drug Metabolite Cardiovascular Disease
    Pholedrine hydrochloride, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine hydrochloride is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine hydrochloride can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine hydrochloride can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome .
    Pholedrine hydrochloride
  • HY-170730
    Tosyl-methamphetamine

    TS-Methamphetamine

    		 Drug Derivative Neurological Disease
    Tosyl-methamphetamine (TS-Methamphetamine) is an amphetamine.
    Tosyl-methamphetamine
  • HY-105879
    Tepirindole

    HR-592 free base

    		 Drug Derivative Neurological Disease
    Tepirindole (HR-592 free base) is an orally active Indole (HY-W001132) derivative. Tepirindole reduces incidence of catalepsy induced by Haloperidol (HY-14538). Tepirindole suppresses the turning behavior induced by Methamphetamine .
    Tepirindole
  • HY-117883
    GZ-793A

    		Monoamine Transporter Neurological Disease
    GZ-793A is an orally active and selective vesicular monoamine transporter-2 (VMAT2) inhibitor, with an Ki of 0.029 µM. GZ-793A inhibits the neurochemical effects of methamphetamine (METH)-induced dopamine release. GZ-793A can be used for research of METH addiction .
    GZ-793A
  • HY-W711852
    Benzamide-d5

    Benzenecarboxamide-d5; Phenylamide-d5

    		 Isotope-Labeled Compounds PARP Endogenous Metabolite Others
    Benzamide-d5 (Benzenecarboxamide-d5) is deuterium labeled Benzamide. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide-d5
  • HY-158014
    JJC8-089

    		Dopamine Transporter Neurological Disease
    JJC8-089 is a dopamine transporter (DAT) inhibitor that may improve motivational dysfunction and increase effortful behavior in goal-directed activities. JJC8-089 significantly reversed the low-effort effects induced by the VMAT-2 inhibitor Tetrabenazine (HY-B0590) in rats and increased the choice of high-effort fixed-ratio 5-bar presses versus food intake. .
    JJC8-089
  • HY-170736
    Methamphetamine ethyl carbamate

    		Drug Derivative Neurological Disease
    Methamphetamine ethyl carbamate is an amphetamine. This product is intended for research and forensic applications.
    Methamphetamine ethyl carbamate
  • HY-119326
    N-Formylmethamphetamine

    		Drug Intermediate Neurological Disease
    N-Formylmethamphetamine is an impurity in the synthesis of methamphetamine. N-Formylmethamphetamine is also a by-product of the Nagai reaction .
    N-Formylmethamphetamine
  • HY-152171
    GZ-11608

    		Monoamine Transporter Neurological Disease
    GZ-11608 is a potent and selective vesicular monoamine transporter-2 (VMAT2) inhibitor with high affinity (Ki = 25 nM). GZ-11608 decreases methamphetamine-induced dopamine release from isolated synaptic vesicles from brain dopaminergic neurons. GZ-11608 exhibits rapid brain penetration and without neurotoxicity. GZ-11608 can be used for the research of methamphetamine use disorder .
    GZ-11608
  • HY-Z0283R
    Benzamide (Standard)

    Benzenecarboxamide (Standard); Phenylamide (Standard)

    		 Reference Standards Endogenous Metabolite PARP Others
    Benzamide (Standard) is the analytical standard of Benzamide. This product is intended for research and analytical applications. Benzamide (Benzenecarboxamide) is a potent poly(ADP-ribose) polymerase (PARP) inhibitor. Benzamide has protective activity against both glutamate- and methamphetamine (METH)-induced neurotoxicity in vitro. Benzamide can attenuate the METH-induced dopamine depletions and exhibits neuroprotective activity in mice, also has no acute effect on striatal dopamine metabolism and does not reduce body temperature .
    Benzamide (Standard)
  • HY-147529
    mGluR2 modulator 3

    		mGluR Neurological Disease
    mGluR2 modulator 3 (compound 1) is a potent mGluR2 positive allosteric modulator with an EC50 value of 0.87 μM. mGluR2 modulator 3 has activity in psychosis disease models such as methamphetamine-induced hyperactivity and mescaline-induced scratching in mice .
    mGluR2 modulator 3
  • HY-121609
    Pholedrine

    		Adrenergic Receptor Cardiovascular Disease Neurological Disease
    Pholedrine, the main metabolite of methamphetamine, is an indirectly acting sympathomimetic amine. Pholedrine is a cardiovascular agent exerting hypertensive and adrenergic effects. Pholedrine can produce mydriatic response and allow localization of the site of the interruption in the oculosympathetic pathway. Pholedrine can be used as a topical eye drop and a diagnostic agent for use in Horner's syndrome .
    Pholedrine
  • HY-157183
    HSMO9

    		Biochemical Assay Reagents Inflammation/Immunology
    HSMO9 is a (+)-methamphetamine (METH)-like hapten that can be coupled to a carrier protein. HSMO9 can be used in vaccine development .
    HSMO9
  • HY-107696
    Ro 04-5595 hydrochloride

    		iGluR Neurological Disease
    Ro 04-5595 hydrochloride is a GluN2B-selective NMDA receptor antagonist (Ki: 31 nM) .
    Ro 04-5595 hydrochloride
  • HY-N14959
    Deacetylravidomycin N-oxide

    		Antibiotic Bacterial Infection Cancer
    Deacetylravidomycin N-oxide is an antibiotic that can be produced by Streptomyces ravidus S50905. Deacetylravidomycin N-oxide is active against Gram-positive bacteria but inactive against Gram-negative bacteria. Deacetylravidomycin N-oxide has antitumor activity against P388 leukemia and methamphetamine A fibrosarcoma .
    Deacetylravidomycin N-oxide
  • HY-115895
    Trebenzomine

    CI-686 free base

    		 Dopamine Receptor Adrenergic Receptor Neurological Disease
    Trebenzomine (CI-686 free base) is a centrally acting psychotropic compound. Trebenzomine has both neuroleptic and stimulant activity. Trebenzomine potentiates Methamphetamine-induced self-stimulation. Trebenzomine reduces septal hyperirritability, suppression of conditioned avoidance behavior, blocks Apomorphine (HY-12723)-induced emesis in dogs .
    Trebenzomine
  • HY-107541R
    O-1602 (Standard)

    		GPR55 Reference Standards Neurological Disease
    O-1602 (Standard) is the analytical standard of O-1602. This product is intended for research and analytical applications. O-1602 is an agonist of GPR55 (G protein-coupled receptor 55). O-1602 reduces the number and activation of hippocampal microglia induced by METH (methamphetamine). O-1602 decreases the expression levels of NLRP3 inflammasome proteins, including NLRP3, ASC and Caspase-1 .
    O-1602 (Standard)
  • HY-120788
    VMAT2-IN-4

    		Monoamine Transporter Others
    VMAT2-IN-4 (compound 11) is a vesicular monoamine transporter-2 (VMAT2) inhibitor. VMAT2-IN-4 inhibits [ 3H]-DTBZ binding (Ki = 560 nM). VMAT2-IN-4 inhibits [ 3H]-DA (Ki = 45 nM) from entering vesicles and being taken up by cells. VMAT2-IN-4 can be used in methamphetamine addiction research .
    VMAT2-IN-4
  • HY-118990
    Lobelane hydrochloride

    		Histone Methyltransferase Neurological Disease
    Lobelane hydrochloride is a biologically active compound that has the activity of inhibiting vesicular monoamine transporter-2 (VMAT2). Lobelane hydrochloride has a low affinity for nicotinic acetylcholine receptors (nAChR), thereby enhancing its selectivity for VMAT2. Synthetic structural changes of lobelane hydrochloride have led to some related analogs that show mild changes in affinity for VMAT2. The most potent synthetic lobelane hydrochloride obtained after structural modification has a K(i) value of 630 nM, showing significant VMAT2 selectivity. The biological activity of lobelane hydrochloride suggests that it has the potential to be used in the development of compounds to inhibit methamphetamine abuse .
    Lobelane hydrochloride
  • HY-W385577A
    (S)-2-Benzylpyrrolidine hydrochloride

    		Drug Derivative Neurological Disease Metabolic Disease Inflammation/Immunology
    (S)-2-Benzylpyrrolidine hydrochloride (Compound s1) serves as a METH hapten scaffold. (S)-2-Benzylpyrrolidine hydrochloride attenuates Methamphetamine-induced hyperlocomotion, hyperthermia and respiratory depression. (S)-2-Benzylpyrrolidine hydrochloride alleviates Fentanyl-induced respiratory depression .
    (S)-2-Benzylpyrrolidine hydrochloride
  • HY-123332
    YM-08050

    		Drug Derivative Neurological Disease
    YM-08050 is a new anti-psychotic and Benzamide (HY-Z0283) derivative. YM-08050 inhibits stereotyped behaviors, conditioned avoidance responses, or spontaneous movements induced by Apomorphine (HY-12723) or Methamphetamine .
    YM-08050
  • HY-W385577
    (S)-2-Benzylpyrrolidine

    		Drug Derivative Neurological Disease Inflammation/Immunology
    (S)-2-Benzylpyrrolidine (Compound s1) serves as a METH hapten scaffold. (S)-2-Benzylpyrrolidine attenuates Methamphetamine-induced hyperlocomotion, hyperthermia and respiratory depression. (S)-2-Benzylpyrrolidine alleviates Fentanyl-induced respiratory depression .
    (S)-2-Benzylpyrrolidine
  • HY-N2332
    Methyllycaconitine

    MLA

    		 nAChR Neurological Disease
    Methyllycaconitine (MLA) is a potent, selective, CNS-penetrant, competitive α7nAChR antagonist. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine can be used for neurological disease research, such as Alzheimer’s disease .
    Methyllycaconitine
  • HY-178885
    (S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid TFA

    		Biochemical Assay Reagents Drug Intermediate Inflammation/Immunology
    (S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid (TFA) (Compound H1) is a Methamphetamine hapten.(S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid (TFA) can be coupled to the BSA, Keyhole limpet hemocyanin molecule. The immunoconjugate H1-KLH strongly induces an antibody response .
    (S)-4-(4-(2-(Methylamino)propyl)phenoxy)butanoic acid TFA
  • HY-182504
    NRA-0562

    		Dopamine Receptor 5-HT Receptor Adrenergic Receptor Neurological Disease
    NRA‑0562 is a dopamine antagonist with high affinities for dopamine D1/D2/D3/D4, 5‑HT2A and α1‑adrenoceptors. NRA-0562 dose‑dependently reverses induced suppression of firing activity in rat A9 and A10 midbrain dopamine neurons, with preferential potency at A10 neurons (ED50 = 0.3 mg/kg). NRA-0562 elevates Fos-like immunoreactivity in rat nucleus accumbens and dorsolateral striatum. NRA-0562 can be used for preclinical research on schizophrenia . .
    NRA-0562
  • HY-179646
    CIAC101

    		Toll-like Receptor (TLR) NO Synthase NF-κB TNF Receptor Interleukin Related Neurological Disease
    CIAC101 is a potent and brain-penetrant TLR4 antagonist with an IC50 of 17.0 nM in NO assay. CIAC101 blocks Lipopolysaccharides (HY-D1056) (LPS)-induced NF-κB activation and reduces the expression of pro-inflammatory mediators (iNOS, IL-1β, TNF-α, and IL-6). CIAC101 robust antineuroinflammatory activity with efficacy against drug-evoked neurobehavioral adaptations. CIAC101 can be used for the research of addiction and neurological disease .
    CIAC101

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: